Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

Shang-Yi Huang; Hsiu-Hsia Lin; Chung-Wu Lin; Chi-Cheng Li; Ming Yao; Jih-Luh Tang; Hsin-An Hou; Woei Tsay; Sheng-Je Chou; Chieh-Lung Cheng; Hwei-Fang Tien

doi:10.18632/oncotarget.11519

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

Shang-Yi Huang _, Hsiu-Hsia Lin, Chung-Wu Lin, Chi-Cheng Li, Ming Yao, Jih-Luh Tang, Hsin-An Hou, Woei Tsay, Sheng-Je Chou, Chieh-Lung Cheng and Hwei-Fang Tien

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:62490-62502. https://doi.org/10.18632/oncotarget.11519

Metrics: PDF 2101 views | HTML 3040 views | ?

Abstract

Shang-Yi Huang1,*, Hsiu-Hsia Lin1,*, Chung-Wu Lin2, Chi-Cheng Li3, Ming Yao1, Jih-Luh Tang1,3, Hsin-An Hou1, Woei Tsay1, Sheng-Je Chou1, Chieh-Lung Cheng1, Hwei-Fang Tien1

1Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan

2Department of Pathology, National Taiwan University, Medical College and Hospital, Taipei, Taiwan

3Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan

*These authors have contributed equally to this work

Correspondence to:

Shang-Yi Huang, email: [email protected]

Keywords: soluble PD-L1, bone marrow plasma, multiple myeloma, autologous transplantation, prognosis

Received: April 25, 2016 Accepted: August 11, 2016 Published: August 23, 2016

ABSTRACT

Autologous hematopoietic stem cell transplantation (AuHSCT) is standard in treating eligible multiple myeloma (MM) patients. However, the outcome after treatment is highly variable. We used ELISA to analyze the levels of soluble PD-L1 (suPD-L1) in bone marrow (BM) plasma from 61 patients with MM at 100 days after AuHSCT. Patients were classified into high (H) and normal-to-low (NL) groups depending on their suPD-L1 levels. Among patients who had a very good partial response (VGPR) or better after AuHSCT, those in the H-group had a shorter response period (RpSCT) as well as shorter overall survival (OS) than those in the NL-group. Multivariate analyses confirmed that a high suPD-L1 level and high-risk cytogenetic abnormalities are independent factors for RpSCT. Our data suggest that suPD-L1 in the BM plasma of MM patients who have VGPR or better after AuHSCT could be used as a biomarker to predict outcome.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11519

Publication Alerts

Research Papers:

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

Abstract